Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Zoetis Inc. (ZTS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for ZTS model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 484M |
| P/E | 30.50 |
| Shares Outstanding | 485M |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 92.60% |
| EPS (last reported FY) | $2.40 |
| EPS (last reported Q) | $0.75 |
| EPS, estimated (last reported Q) | $0.70 |
| Total revenues | $5 B |
| Net income | $1 B |